Artificial Intelligence in Health Care: Benefits and Challenges of Machine Learning Technologies for Medical Diagnostics (open access)

Artificial Intelligence in Health Care: Benefits and Challenges of Machine Learning Technologies for Medical Diagnostics

Report discussing currently available machine learning (ML) medical diagnostic technologies for five selected diseases, emerging ML medical diagnostic technologies, challenges affecting the development and adoption of ML technologies for medical diagnosis, and policy options to help address challenges in the use of artificial intelligence (AI) technologies in health care (Part One). Part Two presents a framework for evaluating and promoting provider adoption of new AI-assisted diagnostic decision support tools (AI-DDS), centered on four integrated domains: 1) Reason to Use, 2) Means to Use, 3) Methods to Use, and 4) Desire to Use.
Date: September 2022
Creator: United States. Government Accountability Office.
System: The UNT Digital Library
Artificial Intelligence in Health Care: Benefits and Challenges of Machine Learning in Drug Development (open access)

Artificial Intelligence in Health Care: Benefits and Challenges of Machine Learning in Drug Development

Artificial intelligence and machine learning (AI/ML) is a set of technologies that includes automated systems able to perform tasks that normally require human intelligence, such as visual perception, speech recognition, and decision-making. AI/ML has promising applications in health care, including drug development. For example, it may have the potential to help identify new treatments, reduce failure rates in clinical trials, and generally result in a more efficient and effective drug development process. However, applying AI/ML technologies within the health care system also raises ethical, legal, economic, and social questions. GAO was asked to conduct a technology assessment on the use of AI technologies in drug development with an emphasis on foresight and policy implications. This report discusses (1) current and emerging AI technologies available for drug development and their potential benefits; (2) challenges to the development and adoption of these technologies; and (3) policy options to address challenges to the use of machine learning in drug development. -- from Foreword
Date: December 2019
Creator: United States. Government Accountability Office.
System: The UNT Digital Library